
CLAIMS:

1. A compound having formula (I):



(I)

wherein

R^1 and R^2 are each members independently selected from the group consisting of H, halogen, CN, C_{1-4} alkyl, C_{1-4} alkoxy and C_{1-4} haloalkyl;

R^{3a} is a member selected from the group consisting of methyl, ethyl, propyl, isopropyl, trifluoromethyl, CH_2CF_3 and CF_2CF_3;

R^{3b} is a member selected from the group consisting of H and D;

R^4 is a member selected from the group consisting of H, C_{1-8} alkyl, -Y and C_{1-4}alkylene-Y; wherein Y is aryl or heteroaryl, and each R^4 is optionally substituted with from one to four substituents selected from the group consisting of halogen, -CN, $-CO_2R^a$, $-CONR^aR^b$, $-C(O)R^a$, $-OC(O)NR^aR^b$, $NR^aC(O)R^b$, $-NR^aC(O)_2R^c$, $-NR^aC(O)NR^aR^b$, $-NR^aR^b$, $-OR^a$, $-S(O)_2NR^aR^b$, $-NR^aS(O)_2R^b$, and $-R^c$, wherein each R^a and R^b is independently selected from hydrogen, C_{1-4} alkyl, C_{1-4} hydroxyalkyl and C_{1-4} haloalkyl, and R^c is selected from C_{1-4} alkyl, C_{1-4} hydroxyalkyl and C_{1-4} haloalkyl;

R^{5a} and R^{5b} are each members independently selected from the group consisting of H, halogen, C_{1-4} alkyl, C_{1-4} alkoxy and CN;

R^{6a} and R^{6b} are each members independently selected from the group consisting of H, C_{1-4} alkyl, C_{1-4} hydroxyalkyl and C_{1-4} haloalkyl; or optionally R^{6a} and R^{6b} are taken together to form oxo (=O);

X is CH or N;

or any salts, solvates, hydrates, N-oxides, tautomers or rotamers thereof.

2. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, wherein R^{3a} is ethyl or isopropyl.

3. The compound of claim **1** or **2**, or a pharmaceutically acceptable salt thereof, wherein R^{3b} is H.

4. The compound of claims **1** or **2**, or a pharmaceutically acceptable salt thereof, wherein R^{3b} is D.

5. The compound of any of claims **1** to **4**, or a pharmaceutically acceptable salt thereof, wherein R^1 is methyl.

6. The compound of any of claims **1** to **5**, or a pharmaceutically acceptable salt thereof, wherein X is CH.


7. The compound of any of claims **1** to **5**, or a pharmaceutically acceptable salt thereof, wherein X is N.

8. The compound of any of claims **1** to **7**, or a pharmaceutically acceptable salt thereof, wherein each of R^{5a} and R^{5b} is independently selected from the group consisting of H, Cl and F.

9. The compound of any of claims **1** to **8**, or a pharmaceutically acceptable salt thereof, wherein each of R^{6a} and R^{6b} is independently selected from the group consisting of H and $C_{1\text{-}4}$ alkyl.

10. The compound of any of claims **1** to **9**, or a pharmaceutically acceptable salt thereof, wherein R^4 is $C_{1\text{-}8}$ alkyl, optionally substituted with -halogen, -CN, $-CO_2R^a$, $-CONR^aR^b$, $-C(O)R^a$, $-OC(O)NR^aR^b$, $-NR^aC(O)R^b$, $-NR^aC(O)_2R^c$, $-NR^aC(O)NR^aR^b$, $-NR^aR^b$, $-OR^a$, $-S(O)_2NR^aR^b$, and $-NR^aS(O)_2R^b$.

11. The compound of claim **1**, having formula (Ia),



(Ia)

wherein

R^1 is selected from the group consisting of Cl and CH_3;

R^{3b} is selected from the group consisting of H and D;

R^4 is a member selected from the group consisting of H and C_{1-8} alkyl, wherein the C_{1-8} alkyl is optionally substituted with $-CONR^aR^b$, $-OC(O)NR^aR^b$, $-NR^aC(O)R^b$, $-NR^aC(O)_2R^c$, $-NR^aR^b$, and $-OR^a$, wherein each R^a and R^b is independently selected from hydrogen, C_{1-4} alkyl, C_{1-4} hydroxyalkyl and C_{1-4} haloalkyl, and R^c is selected from C_{1-4} alkyl, C_{1-4} hydroxyalkyl and C_{1-4} haloalkyl;

R^{5a} and R^{5b} are each members independently selected from the group consisting of H, F, Cl and CH_3;


R^{6a} and R^{6b} are each members independently selected from the group consisting of H, C_{1-4} alkyl, C_{1-4} hydroxyalkyl and C_{1-4} haloalkyl; or optionally R^{6a} and R^{6b} are taken together to form oxo (=O);

or any salts, solvates, hydrates, N-oxides or rotamers thereof.

12. The compound of claim **11**, or a pharmaceutically acceptable salt thereof, wherein R^{3b} is H; R^4 is H or CH_3; R^{5a} is H, F or Cl; R^{5b} is H, F, Cl; R^{6a} and R^{6b} are independently selected from the group consisting of H and CH_3, or are taken together to form oxo (=O).

13. The compound of claim **11**, or a pharmaceutically acceptable salt thereof, wherein R^{3b} is D; R^4 is H or CH_3; R^{5a} is H, F or Cl; R^{5b} is H, F, Cl; R^{6a} and R^{6b} are independently selected from the group consisting of H and CH_3, or are taken together to form oxo (=O).

14. The compound of claim **1**, having formula (Ib),



(Ib)

wherein

R^1 is selected from the group consisting of Cl and CH_3;

R^{3b} is selected from the group consisting of H and D;

R^4 is a member selected from the group consisting of H and C_{1-8} alkyl, wherein the C_{1-8} alkyl is optionally substituted with $-CONR^aR^b$, $-OC(O)NR^aR^b$, $-NR^aC(O)R^b$, $-NR^aC(O)_2R^c$, $-NR^aR^b$, and $-OR^a$, wherein each R^a and R^b is independently selected from hydrogen, C_{1-4} alkyl, C_{1-4} hydroxyalkyl and C_{1-4} haloalkyl, and R^c is selected from C_{1-4} alkyl, C_{1-4} hydroxyalkyl and C_{1-4} haloalkyl;

R^{5a} and R^{5b} are each members independently selected from the group consisting of H, F, Cl and CH_3;






















R^{6a} and R^{6b} are each members independently selected from the group consisting of H, C_{1-4} alkyl, C_{1-4} hydroxyalkyl and C_{1-4} haloalkyl; or optionally R^{6a} and R^{6b} are taken together to form oxo (=O);

or any salts, solvates, hydrates, N-oxides or rotamers thereof.





















15. The compound of claim **14**, or a pharmaceutically acceptable salt thereof, wherein R^{3b} is H; R^4 is H or CH_3; R^{5a} is H, F or Cl; R^{5b} is H, F, Cl; R^{6a} and R^{6b} are independently selected from the group consisting of H and CH_3, or are taken together to form oxo (=O).

16. The compound of claim **14**, or a pharmaceutically acceptable salt thereof, wherein R^{3b} is D; R^4 is H or CH_3; R^{5a} is H, F or Cl; R^{5b} is H, F, Cl; R^{6a} and R^{6b} are independently selected from the group consisting of H and CH_3, or are taken together to form oxo (=O).














17. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

















and


3

1 **18.** A pharmaceutical composition comprising a compound of any of claims **1**
2 to **17**.

1 **19.** The pharmaceutical composition of claim **18,** further comprising one or
2 more additional therapeutic agents.

1 **20.** The pharmaceutical composition of claim **19** wherein the one or more
2 additional therapeutic agent is selected from the group consisting of a cytotoxic chemotherapy,
3 anti-cancer or anti-tumor vaccines, anti-immunocytokine therapies, immunocytokine therapies,
4 chimeric antigen receptor (CAR) T cell receptors, gene transfer therapy, and checkpoint
5 inhibitors.

21. The pharmaceutical composition of claim **19** wherein the one or more additional therapeutic agent is selected from the group consisting of: drugs that block the activity of CTLA-4 (CD152), PD-1 (CD279), PDL-1 (CD274), TIM-3, LAG-3 (CD223), VISTA, KIR, NKG2A, BTLA, PD-1H, TIGIT, CD96, 4-1BB (CD137), 4-1BBL (CD137L), GARP, CSF-1R, A2AR, CD73, CD47, tryptophan 2,3-dioxygenase (TDO) or indoleamine 2,3 dioxygenase (IDO), and agonists of OX40, GITR, 4-1BB, ICOS, STING or CD40.

22. Use of a compound of any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition for treating a CXCR2-mediated disease or condition in a subject in need thereof.

23. Use of claim **22**, wherein the CXCR2-mediated disease is an acute or chronic inflammatory disorder.

24. Use of claim **23**, wherein the CXCR2-mediated acute or chronic inflammatory disorder is selected from the group consisting of psoriasis, rheumatoid arthritis, radiation induced fibrotic lung disease, autoimmune bullous dermatosis (AIBD), chronic obstructive pulmonary disease, and ozone-induced airway inflammation.

25. Use of claim **22**, wherein the CXCR2-mediated disease is a cancer selected from the group consisting of rhabdomyocarcoma, Lewis lung carcinoma (LLC), non-small cell lung cancer, esophageal squamous cell carcinoma, esophageal adenocarcinoma, renal cell carcinoma (RCC), colorectal cancer (CRC), acute myeloid leukemia (AML), breast cancer, gastric cancer, prostatic small cell neuroendocrine carcinoma (SCNC), liver cancer, glioblastoma, liver cancer, oral squamous cell carcinoma, head and neck squamous cell carcinoma, pancreatic cancer, thyroid papillary cancer, intrahepatic cholangiocellular carcinoma, hepatocellular carcinoma, bone cancer, and nasopharyngeal carcinoma.

26. Use of claim **25**, wherein the compound or a pharmaceutically acceptable salt thereof, is to be used to treat cancer alone or in combination with one or more other anti-cancer therapies.

27. Use of claim **26**, wherein the compound or a pharmaceutically acceptable salt thereof, is to be used to treat cancer in combination with one or more of a cytotoxic chemotherapy, an anti-cancer vaccine, an anti-tumor vaccines, an anti-immunocytokine, an immunocytokine therapy, and a chimeric antigen receptor (CAR) T cell receptors, gene transfer therapy.

28. Use of claim **26**, wherein the compound or a pharmaceutically acceptable salt thereof, is to be used to treat cancer in combination with one or more checkpoint inhibitor.

29. Use of claim **26** wherein the one or more other anti-cancer therapy is selected from the group consisting of: drugs that block the activity of CTLA-4 (CD152), PD-1 (CD279), PDL-1 (CD274), TIM-3, LAG-3 (CD223), VISTA, KIR, NKG2A, BTLA, PD-1H, TIGIT, CD96, 4-1BB (CD137), 4-1BBL (CD137L), GARP, CSF-1R, A2AR, CD73, CD47, tryptophan 2,3-dioxygenase (TDO) or indoleamine 2,3 dioxygenase (IDO), and agonists of OX40, GITR, 4-1BB, ICOS, STING or CD40.

30. A compound of any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of any one of claims 18 to 21 for use in treating a CXCR2-mediated disease or condition in a subject in need thereof.